Lovenox (enoxaparin sodium injection)

August 17, 2004

Audience: Physicians, pharmacists, and other healthcare providers

FDA and Aventis Pharmaceuticals revised the CLINICAL PHARMACOLOGY, PRECAUTIONS, and DOSAGE AND ADMINISTRATION sections of labeling, describing the need for a dosage adjustment for patients with severe renal impairment (creatinine clearance <30mL/min) who have increased exposure to enoxaparin. No specific dosage adjustment is required in patients with mild or moderate renal impairment and in low-weight patients. However, low-weight patients should be observed carefully for signs and symptoms of bleeding.

[March 2004 Letter - Aventis]
[July 2004 Label - Aventis]

View comments

Hide
(web4)